Attached files
file | filename |
---|---|
EX-32.2 - CuraTech Industries, Inc. | v166572_ex32-2.htm |
EX-31.1 - CuraTech Industries, Inc. | v166572_ex31-1.htm |
EX-32.1 - CuraTech Industries, Inc. | v166572_ex32-1.htm |
EX-31.2 - CuraTech Industries, Inc. | v166572_ex31-2.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM
10-Q
(Mark
One)
x
|
QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF
|
|
THE
SECURITIES EXCHANGE ACT OF 1934
|
For the
quarterly period ended June 30, 2009
¨
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF
THE
|
|
SECURITIES
EXCHANGE ACT OF 1934
|
For the
transition period from ____________ to____________
Commission
file number 000-51140
CuraTech Industries,
Inc.
(Exact
name of registrant as specified in its charter)
NEVADA
|
87-0649332
|
(State
or other jurisdiction of
|
(I.R.S.
Employer identification No.)
|
incorporation
or organization)
|
6337
Highland Drive, No. 1053
Salt Lake City, Utah
84121
(Address
of principal executive offices)
Registrant’s
telephone number: (801) 616-2355
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes o No x
Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes ¨ No ¨
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
|
Non-accelerated
filer ¨ (Do
not check if a smaller reporting company)
|
Smaller
reporting company x
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes ¨ No x
APPLICABLE
ONLY TO CORPORATE ISSUERS
State the
number of shares outstanding of each of the issuer’s classes of common equity,
as of the latest practicable date: As of December
10,
2009, there were 17,146,699 shares of the issuer’s common stock
issued and outstanding. There were also stock subscriptions payable
for an additional 505,400
shares as of that date.
CURATECH
INDUSTRIES, INC.
FORM
10-Q
TABLE
OF CONTENTS
Page
|
||
PART
I – FINANCIAL INFORMATION
|
||
Item
1. Financial Statements (Unaudited)
|
3
|
|
Condensed
Consolidated Balance Sheets — As
of June 30, 2009 (Unaudited)
|
||
and
December 31, 2008
|
5
|
|
Condensed
Consolidated Statements of Operations for the Three and Six
Months
|
||
Ended
June 30, 2009 and 2008, and for the period from inception on April 25,
2006
|
||
through
June 30, 2009 (Unaudited)
|
6
|
|
Condensed
Consolidated Statements of Cash Flows for the Six
Months
|
||
Ended
June 30, 2009 and 2008 and for the period from inception on April 25,
2006
|
||
through
June 30, 2009 (Unaudited)
|
7
|
|
Notes
to Condensed Consolidated Financial Statements
(Unaudited)
|
8
|
|
Item
2. Management’s Discussion and Analysis of
Financial
|
||
Condition
and Results of Operations
|
10
|
|
Item
3. Quantitative and Qualitative Disclosures
About
|
||
Market
Risk
|
13
|
|
Item
4. Controls and Procedures
|
13
|
|
PART
II – OTHER INFORMATION
|
||
Item
1. Legal Proceedings
|
13
|
|
Item
1A. Risk Factors
|
14
|
|
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds
|
14
|
|
Item
3. Defaults Upon Senior Securities
|
14
|
|
Item
4. Submission of Matters to a Vote of Security
Holders
|
14
|
|
Item
5. Other Information
|
14
|
|
Item
6. Exhibits
|
14
|
2
PART I -
FINANCIAL INFORMATION
Item
1. Financial Statements.
The
condensed consolidated balance sheets of CuraTech Industries, Inc., a Nevada
corporation (“CuraTech” or the “Company”) as of June 30, 2009 (unaudited) and
December 31, 2008, the related unaudited condensed consolidated statements of
operations for the three and six month periods ended June 30, 2009 and June 30,
2008 and for the period from inception on April 25, 2006 through June 30, 2009,
the related unaudited condensed consolidated statements of cash flows for the
six month periods ended June 30, 2009 and June 30, 2008 and for the
period from inception on April 25, 2006 through June 30, 2009, and the
notes to the unaudited condensed consolidated financial statements
follow. The financial statements have been prepared by CuraTech’s
management in conformity with United States generally accepted accounting
principles. In the opinion of management, all adjustments considered
necessary for a fair presentation of the results of operations and financial
position have been included and all such adjustments are of a normal recurring
nature. Operating results for the period ended June 30, 2009, are not
necessarily indicative of the results that can be expected for the year ending
December 31, 2009.
The names
“CuraTech”, “we”, “our” and “us” used in this report refer to CuraTech
Industries, Inc.
CURATECH
INDUSTRIES, INC.
(A
Development Stage Company)
FINANCIAL
STATEMENTS
June 30,
2009
3
CURATECH
INDUSTRIES, INC.
(A
DEVELOPMENT STAGE COMPANY)
INDEX
TO FINANCIAL STATEMENTS
Page
|
||
Condensed
Consolidated Balance Sheets – June 30, 2009
(Unaudited)
|
||
and
December 31, 2008
|
5
|
|
Condensed
Consolidated Statements of Operations (Unaudited) for the Three and
Six Months
|
||
Ended
June 30, 2009 and 2008, and
for the period from inception on April 25, 2006
through
|
||
June 30,
2009
|
6
|
|
Condensed
Consolidated Statements of Cash Flows (Unaudited) for the Six
Months
|
||
Ended
June 30, 2009 and 2008, and
for the period from inception on April 25, 2006
through
|
||
June
30, 2009
|
7
|
|
Notes
to the Unaudited
Condensed Consolidated Financial Statements
|
8 |
4
CURATECH
INDUSTRIES, INC.
(A
Development Stage Company)
Condensed
Consolidated Balance Sheets
June 30,
|
December 31,
|
|||||||
2009
|
2008
|
|||||||
(Unaudited)
|
||||||||
ASSETS
|
||||||||
CURRENT
ASSETS
|
||||||||
Cash
|
$ | 8,314 | $ | 8,305 | ||||
Note
receivable
|
200,000 | - | ||||||
Interest
receivable
|
4,979 | - | ||||||
Total
Current Assets
|
213,293 | 8,305 | ||||||
FIXED
ASSETS, Net
|
3,406 | 4,087 | ||||||
OTHER
ASSETS
|
||||||||
Real
estate investment
|
230,862 | 230,862 | ||||||
Total
Other Assets
|
230,862 | 230,862 | ||||||
TOTAL
ASSETS
|
$ | 447,561 | $ | 243,254 | ||||
LIABILITIES AND STOCKHOLDERS'
EQUITY
|
||||||||
CURRENT
LIABILITIES
|
||||||||
Accounts
payable and accrued expenses
|
$ | 51,027 | $ | 13,467 | ||||
Accrued
officer salaries
|
87,562 | 66,434 | ||||||
Notes
payable - related party
|
251,500 | - | ||||||
Notes
payable
|
40,000 | - | ||||||
Accrued
interest payable - related party
|
2,013 | - | ||||||
Accrued
interest payable
|
1,600 | - | ||||||
Total
Current Liabilities
|
433,702 | 79,901 | ||||||
TOTAL
LIABILITIES
|
433,702 | 79,901 | ||||||
STOCKHOLDERS'
EQUITY
|
||||||||
Common
stock: 25,000,000 shares authorized;
|
||||||||
$0.001
par value; 16,780,199 shares issued
|
||||||||
and
outstanding
|
16,780 | 16,780 | ||||||
Additional
paid-in capital
|
4,337,013 | 4,337,013 | ||||||
Stock
subscriptions receivable
|
(99,252 | ) | (99,252 | ) | ||||
Stock
subscriptions payable
|
703,900 | 580,900 | ||||||
Accumulated
deficit
|
(4,944,582 | ) | (4,672,088 | ) | ||||
Total
Stockholders' Equity
|
13,859 | 163,353 | ||||||
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY
|
$ | 447,561 | $ | 243,254 |
The
accompanying notes are an integral part of these financial
statements.
5
CURATECH
INDUSTRIES, INC.
(A
Development Stage Company)
Condensed
Consolidated Statements of Operations
(Unaudited)
From Inception
|
||||||||||||||||||||
For the Three
|
For the Six
|
on April 25,
|
||||||||||||||||||
Months Ended
|
Months Ended
|
2006 Through
|
||||||||||||||||||
June 30,
|
June 30,
|
June 30,
|
||||||||||||||||||
2009
|
2008
|
2009
|
2008
|
2009
|
||||||||||||||||
REVENUES
|
$ | - | $ | - | $ | - | $ | - | $ | - | ||||||||||
OPERATING
EXPENSES
|
||||||||||||||||||||
General
and administrative
|
52,953 | 50,533 | 95,001 | 155,261 | 2,065,459 | |||||||||||||||
Consulting
|
16,660 | 15,050 | 53,178 | 15,900 | 2,033,463 | |||||||||||||||
Officer
compensation
|
62,500 | 105,000 | 125,000 | 105,000 | 375,000 | |||||||||||||||
Depreciation
|
341 | 341 | 681 | 681 | 3,406 | |||||||||||||||
Total
Operating Expenses
|
132,454 | 170,924 | 273,860 | 276,842 | 4,477,328 | |||||||||||||||
LOSS
FROM OPERATIONS
|
(132,454 | ) | (170,924 | ) | (273,860 | ) | (276,842 | ) | (4,477,328 | ) | ||||||||||
OTHER
INCOME (EXPENSES)
|
||||||||||||||||||||
Impairment
of assets
|
- | - | - | - | (472,500 | ) | ||||||||||||||
Interest
expense
|
(1,600 | ) | - | (3,613 | ) | - | (3,613 | ) | ||||||||||||
Interest
income
|
3,000 | - | 4,979 | - |
8,859
|
|||||||||||||||
Total
Other Income (Expenses)
|
1,400 | - | 1,366 | - | (467,254 | ) | ||||||||||||||
NET
LOSS
|
$ | (131,054 | ) | $ | (170,924 | ) | $ | (272,494 | ) | $ | (276,842 | ) | $ | (4,944,582 | ) | |||||
BASIC
LOSS PER SHARE
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.01 | ) | ||||||||
WEIGHTED
AVERAGE NUMBER OF SHARES OUTSTANDING
|
16,780,199 | 18,580,199 | 16,780,199 | 18,580,199 |
The
accompanying notes are an integral part of these financial
statements.
6
CURATECH
INDUSTRIES, INC.
(A
Development Stage Company)
Condensed
Consolidated Statements of Cash Flows
(Unaudited)
From Inception
|
||||||||||||
on April 25,
|
||||||||||||
For the Six Months Ended
|
2006 Through
|
|||||||||||
June 30,
|
June 30,
|
|||||||||||
2009
|
2008
|
2009
|
||||||||||
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||||||
Net
loss
|
$ | (272,494 | ) | $ | (276,842 | ) | $ | (4,944,582 | ) | |||
Adjustments
to reconcile net loss to
|
||||||||||||
net
cash used by operating activities:
|
||||||||||||
Depreciation
|
681 | 681 | 3,405 | |||||||||
Common
stock issued for services
|
- | - | 3,153,000 | |||||||||
Conversion
of note receivable to officer salaries
|
77,885 | - | ||||||||||
Impairment
of assets
|
- | - | 472,500 | |||||||||
Services
contributed by officers
|
- | - | 7,000 | |||||||||
Changes
in operating assets and liabilities
|
||||||||||||
Increase
in interest receivable
|
(4,979 | ) | - | (54,979 | ) | |||||||
Increase
in accrued expenses - related parties
|
21,128 | - | 20,328 | |||||||||
Increase
in accounts payable and accrued expense
|
37,560 | 8,341 | 112,973 | |||||||||
Increase
in accrued interest - related parties
|
2,013 | - | 2,013 | |||||||||
Increase
in accrued interest
|
1,600 | - | 1,600 | |||||||||
Net
Cash Used by Operating Activities
|
(214,491 | ) | (189,935 | ) | (1,226,742 | ) | ||||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||||||
Purchase
of investment
|
- | - | (150,000 | ) | ||||||||
Purchase
of notes receivable
|
(200,000 | ) | - | (200,000 | ) | |||||||
Cash
paid for real estate
|
- | (230,862 | ) | (230,862 | ) | |||||||
Net
Cash Used by Investing Activities
|
(200,000 | ) | (230,862 | ) | (580,862 | ) | ||||||
CASH
FLOWS FROM FINIANCING ACTIVITIES
|
||||||||||||
Common
stock issued for cash
|
- | - | 603,559 | |||||||||
Cash
received in acquisition
|
- | - | 137,673 | |||||||||
Cash
received on note payable
|
40,000 | - |
45,288
|
|||||||||
Cash
received on note payable - related
|
281,500 | - | 281,500 | |||||||||
Cash
paid on notes payable - related
|
(30,000 | ) | - | (30,000 | ) | |||||||
Cash
received on subscriptions receivable
|
- | - | 73,998 | |||||||||
Cash
received on subscriptions payable
|
123,000 | 450,900 | 703,900 | |||||||||
Net
Cash Provided by Financing Activities
|
414,500 | 450,900 | 1,815,918 | |||||||||
NET
INCREASE IN CASH
|
9 | 30,103 | 8,314 | |||||||||
CASH
AT BEGINNING OF PERIOD
|
8,305 | 58,160 | - | |||||||||
CASH
AT END OF PERIOD
|
$ | 8,314 | $ | 88,263 | $ | 8,314 | ||||||
SUPPLIMENTAL
DISCLOSURES OF
|
||||||||||||
CASH
FLOW INFORMATION
|
||||||||||||
CASH
PAID FOR:
|
||||||||||||
Interest
|
$ | - | $ | - | $ | - | ||||||
Income
Taxes
|
$ | - | $ | - | $ | - | ||||||
NON-CASH
FINANCING ACTIVITIES
|
||||||||||||
Common
stock issued for services
|
$ | - | $ | - | $ | 3,153,000 | ||||||
Services
contributed by director
|
$ | - | $ | - | $ | 7,000 |
The
accompanying notes are an integral part of these financial
statements.
7
CURATECH
INDUSTRIES, INC.
(A
Development Stage Company)
Notes to
the Unaudited
Condensed Consolidated Financial Statements
June 30,
2009
NOTE 1
- BASIS OF FINANCIAL STATEMENT PRESENTATION
The
accompanying unaudited condensed financial statements have been prepared by the
Company pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information and footnote disclosures normally included in
financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted in
accordance with such rules and regulations. The information furnished
in the interim condensed financial statements includes normal recurring
adjustments and reflects all adjustments, which, in the opinion of management,
are necessary for a fair presentation of such financial
statements. Although management believes the disclosures and
information presented are adequate to make the information not misleading, it is
suggested that these interim condensed financial statements be read in
conjunction with the Company's most recent audited financial statements and
notes thereto included in its December 31, 2008 Annual Report on Form
10-K of the Company. Operating results for the period ended June 30,
2009 are not necessarily indicative of the results that may be expected for the
year ending December 31, 2009.
NOTE 2
- GOING CONCERN
The
Company's financial statements are prepared using accounting principles
generally accepted in the United States of America applicable to a going concern
which contemplates the realization of assets and liquidation of liabilities in
the normal course of business. The Company has not established
revenues sufficient to cover its operating costs and allow it to continue as a
going concern. Management intends to increase operations
through expanding its operations into other locals, in the interim, management
and primary shareholders are committed to meeting the Company’s minimal
operating expenses.
NOTE 3
- AGREEMENT AND PLAN OF MERGER
On
October 26, 2006, the Company completed the acquisition of MedaCure
International, Inc., a Nevada corporation located in Salt Lake City, Utah
(“MedaCure”). The acquisition was consummated pursuant to an agreement entered
into on June 22, 2006, whereby the Company agreed to merge its newly created,
wholly-owned subsidiary, CuraTech Acquisitions, Inc., with and into MedaCure
with MedaCure being the surviving entity as the Company’s wholly-owned
subsidiary.
Prior to
completion of the acquisition the Company changed its corporate name to CuraTech
Industries, Inc. The Company also changed its corporate domicile from the State
of Utah to Nevada. Also, the Company added three new directors, each
nominated by MedaCure, to its Board of Directors.
From the
consummation of the Merger Agreement, the Company has begun the development and
bringing to market a certain health supplement that is intended to enhance and
build-up the body’s natural immune system defenses. The Company intends to
commence commercial marketing of its supplement in the near future primarily
outside the U.S. Initial marketing in the U.S. will primarily be to the
veterinarian market for use in treating animals. The Company also intends to
initiate a collaboration and partnering program that will focus on developing
business alliances designed to generate sales, applications and marketing
opportunities.
NOTE 4
- SIGNIFICANT EVENTS
Equity Activity –
During the six months ended June 30, 2009 the Company received $123,000 from
various investors in exchange for 123,000 shares of common stock at $1.00 per
share. As of June 30, 2009 the shares have not been issued;
therefore, this amount has been recorded as stock subscriptions payable in the
Company’s financial statements.
8
CURATECH
INDUSTRIES, INC.
(A
Development Stage Company)
Notes to
the Unaudited
Condensed Consolidated Financial Statements (Continued)
June 30,
2009
NOTE 4
- SIGNIFICANT EVENTS
(Continued)
Notes Payable – Related
Party – During the six months ended June 30, 2009, the Company received a
total of $281,500 in cash from related parties. These amounts have
been recorded as notes payable – related parties. Each note is
unsecured, bears interest at a rate of 8.0% per annum, and is due on
demand. As of June 30, 2009 the Company had made payments on these
notes amounting to $30,000. Accrued interest payable on these notes
totaled $2,013 as of June 30, 2009.
Notes Payable –
During the six months ended June 30, 2009, the Company received a total of
$40,000 in cash from an unrelated third party. This amount accrues
interest at a rate of 24% per annum, and is due in full, including accrued
interest, on October 27, 2009. Accrued interest payable on this note
totaled $1,600 as of June 30, 2009. This note
is subsequently in default.
Notes Receivable –
During the six months ended June 30, 2009, the Company loaned a total of
$200,000 to various unrelated entities. These amounts have been
recorded as notes receivable in these financial statements. The notes
are unsecured, bear interest at a rate of 9.5% per annum, and are due on
demand. The Company recorded $4,979 in interest income on these notes
during the six months ended June 30, 2009.
NOTE 5
- SUBSEQUENT EVENTS
Stock
issuances –
Subsequent to June 30, 2009 the Company issued 366,500 shares of common stock to
various unrelated entities. Of these shares, 168,000 were issued for
cash at $1.00 per share, and the remaining 198,500 were issued pursuant to
various stock subscriptions payable.
The
Company evaluated subsequent events from the balance sheet date through December
9, 2009.
9
Item
2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations.
The following information should be
read in conjunction with the financial statements and notes thereto appearing
elsewhere in this Form 10-Q.
Recent
Events
Equity Activity – During the six months
ended June 30, 2009 the Company received $123,000 from various investors in
exchange for 123,000 shares of common stock at $1.00 per share. As of
June 30, 2009 the shares have not been issued; therefore, this amount has been
recorded as stock subscriptions payable in the Company’s financial
statements.
Notes Payable – Related Party – During
the six months ended June 30, 2009, the Company received a total of $281,500 in
cash from related parties. These amounts have been recorded as notes
payable – related parties. Each note is unsecured, bears interest at
a rate of 8.0% per annum, and is due on demand. As of June 30, 2009
the Company had made payments on these notes amounting to
$30,000. Accrued interest payable on these notes totaled $2,013 as of
June 30, 2009.
Notes
Payable – During the six months ended June 30, 2009, the Company received a
total of $40,000 in cash from an unrelated third party. This amount
accrues interest at a rate of 24% per annum, and is due in full, including
accrued interest, on October 27, 2009. Accrued interest payable on
this note totaled $1,600 as of June 30, 2009. This note
is subsequently in default.
Notes
Receivable – During the six months ended June 30, 2009, the Company loaned a
total of $200,000 to various unrelated entities. These amounts have
been recorded as notes receivable in these financial statements. The
notes are unsecured, bear interest at a rate of 9.5% per annum, and are due on
demand. The
Company recorded $4,979 in interest income on these notes during the six months
ended June 30, 2009.
As of June 30, 2009, the Company owed
its Chief Executive Officer $87,562 in accrued wages.
Plan
of Operation
Following
the completion of the acquisition of MedaCure on October 26, 2006, we have
become engaged in attempting to develop a market for MedaCure’s proprietary
health supplement formula that is believed to enhance and build-up the body’s
natural immune system defenses in both humans and animals. In
November 2008, we engaged a third party manufacturer to begin manufacturing the
MedaCure product. A total of 785,000 capsules have been manufactured
to date. Manufacturing
and marketing costs have been incurred primarily by independent contractors with
whom the Company has no contractual agreements. We anticipate
consummating formal manufacturing, marketing, and sales agreements with respect
to our product at such time a viable market for the product has been
established. Our recent strategic emphasis has been to attempt to
develop a market for our product in the country of India. Our next priority will be to establish
new facilities for our corporate headquarters and to warehouse the product.
Management is seeking a 3,000 square foot facility that can be leased on a
long-term basis. The facility will also handle shipping of product. We have not
selected a final site, but we are searching for one in Utah County,
Utah.
Contemporaneous
with selecting the site for our headquarters and warehouse, we will be creating
a distribution network that will focus on initiating a collaboration and
partnering program and developing business alliances designed to generate sales,
applications and marketing opportunities. At present, we are negotiating with
two groups of potential distributors. We anticipate that during the
next 12 months we will hire approximately 10-15 persons, 3-5 for administrative
duties,
and 7-10 for sales and marketing.
We
estimate that during the next 12 months we will need approximately $500,000 to
establish our headquarters/warehouse facility, establish a sales and
distribution network, and begin selling activities. We anticipate
that the source of the remaining funds needed will be from the private sale of
securities and/or other financing activities conducted by our officers and
directors. We hope to raise approximately $500,000 during the
remaining portion of 2009, although there presently are no commitments for
funds, and we cannot offer any assurance that we will be able to raise such
funds on terms acceptable to the Company.
Inflation
In the
opinion of management, inflation has not and will not have a material effect on
our operations in the immediate future. Management will continue to monitor
inflation and evaluate the possible future effects of inflation on our business
and operations.
10
Results
of Operations
Three
Months Ended June 30, 2009 Compared to the Three Months Ended June 30,
2008.
Revenues
from continuing operations for the three months ended June 30, 2009 were $-0-
compared to $-0- for the three month period ended June 30,
2008. This lack
of revenues was due primarily to the fact that our revenue stream pertaining to
the Medacure subsidiary has not yet been developed. We
anticipate such sales may begin as early as fourth quarter
2009.
Total operating expenses for the three
month period ended June 30, 2009 were $132,454, a decrease of $38,470 from the
$170,924 of total operating expenses incurred in the three month period ended
June 30, 2008. General and administrative expenses for the three
month period ended June 30, 2009 were $52,953, an increase of $2,420 from the
$50,533 of general and administrative expenses incurred in the three months
ended June 30, 2008. Consulting expenses totaled $16,660 in the three
months ended June 30, 2009, an increase of $1,610 from the $15,050 of consulting
expenses incurred in the three months ended June 30, 2008. Officer
compensation totaled $62,500 in the three months ended June 30, 2009, a decrease
of $42,500 from the $105,000 of officer compensation incurred in the three
months ended June 30, 2008. The Company anticipates that officer
compensation should remain at the current quarterly level for the rest of
2009.
We reported a net loss of $131,054, or
$.01 per share, for the three months ended June 30, 2009, which is $39,870 less
than the $170,924 net loss, or $0.01 per share, incurred during the three months
ended June 30, 2008. The decreased net loss is primarily
attributed to the decreases in officer compensation and general and
administrative expenses incurred in the later period.
Six
Months Ended June 30, 2009 Compared to the Six Months Ended June 30,
2008
Revenues
from continuing operations for the six month period ended June 30, 2009 were
$-0- compared to $-0- for the six month period ended June 30,
2008. This lack
of revenues was due primarily to the fact that our revenue stream pertaining to
the Medacure subsidiary has not yet been developed. We
anticipate such sales may begin as early as fourth quarter
2009.
Total operating expenses for the six
month period ended June 30, 2009 were $273,860, a decrease of $2,982 from the
$276,842 of total operating expenses incurred in the six month period ended June
30, 2008. General and administrative expenses for the six month
period ended June 30, 2009 were $95,001, a decrease of $60,260 from the $155,261
of general and administrative expenses incurred in the six months ended June 30,
2008. Consulting expenses totaled $53,178 in the six months ended
June 30, 2009, an increase of $37,278 from the $15,900 of consulting expenses
incurred in the six months ended June 30, 2008. Officer compensation
totaled $125,000 in the six months ended June 30, 2009, an increase of $20,000
from the $105,000 of officer compensation incurred in the six months ended June
30, 2009. The Company anticipates that officer compensation should
remain at the current quarterly level for the rest of 2009.
We incurred a net loss of $272,494, or
$0.02 per share, during the six months ended June 30, 2009, which is $4,348 less
than the $276,842 net loss, or $0.01 per share, incurred during the six months
ended June 30, 2008. The reduced net loss is primarily attributed to
the substantial reduction in general and administrative expenses partially
offset by increases in consulting expense and officer compensation incurred
during the six months ended June 30, 2009.
Liquidity
and Capital Resources
At June 30, 2009, our current assets
consisted of cash on hand of $8,314, a note receivable of $200,000 and interest
receivable of $4,979. We believe that current cash on hand is not
sufficient to satisfy our cash requirements for the next twelve months, which we
estimate to be approximately $500,000. Due to the fact that our
limited operations have not generated cash flow sufficient to cover ongoing
business expenses, we may have to rely on our directors, or on outside sources,
to provide additional funds. However, we have no agreements with
anyone to provide future funds to our Company. If our directors are unable to
provide future funding, if the need arises, we may have to look at alternative
sources of funding. There is no assurance that such funds will be available or,
that even if they are available, that they will be available on terms that will
be acceptable to us. In the event we are unable to secure necessary future
funding, we may have to curtail our business or cease operations
completely. At the present time, the Company is attempting to raise
additional funds through a private placement offering of the Company’s common
stock. No one is obligated to purchase any additional shares in the
offering.
At June 30, 2009, we had total assets
of $447,561 and stockholders' equity of $13,859 compared to total assets of
$243,254 and total stockholders' equity of $163,353 at December 31,
2008.
11
All of
the Company’s liabilities of $433,702
as of June 30, 2009 are current liabilities due within the next year, and
primarily consist of $251,500 in notes payable-related party, $87,562 accrued
officer salaries, $40,000 in notes payable, and $51,027 in accounts payable and
accrued expenses.
The Company expects to hire 10-15
employees in the next 12 months.
Capital
Expenditures
The Company expended no amounts on
capital expenditures during the six months ended June 30, 2009. The
Company has no current plans for capital expenditures.
Critical
Accounting Policies
In the notes to the audited
consolidated financial statements for the year ended December 31, 2008, included
in the Company’s Annual Report on Form 10-K, the Company discusses those
accounting policies that are considered to be significant in determining the
results of operations and its financial position. The Company believes that the
accounting principles utilized by it conform to accounting principles generally
accepted in the United States of America.
The preparation of financial statements
requires Company management to make significant estimates and judgments that
affect the reported amounts of assets, liabilities, revenues and expenses. By
their nature, these judgments are subject to an inherent degree of uncertainty.
On an on-going basis, the Company evaluates estimates. The Company bases its
estimates on historical experience and other facts and circumstances that are
believed to be reasonable, and the results form the basis for making judgments
about the carrying value of assets and liabilities. The actual
results may differ from these estimates under different assumptions or
conditions.
Going
Concern
There is a substantial doubt as to the
Company’s ability to continue as a going concern as a result of recurring
losses, lack of revenue-generating activities and a deficit accumulated during
the development stage in the amount of $4,944,582 as of June 30, 2009. The
Company’s ability to continue as a going concern is subject to the ability of
the Company to realize a profit from operations and /or obtain funding from
outside sources. Since the Company has no revenue generating
operations, our plan to address the Company’s ability to continue as a going
concern over the next twelve months includes obtaining additional funding from
the sale of our securities. Although we believe that we will be able
to obtain the necessary funding to allow the Company to remain a going concern
through the methods discussed above, there can be no assurances that such
methods will prove successful.
Net
Operating Loss
We have accumulated approximately
$1,079,847
of net operating loss carryforwards as of June 30, 2009, which may be offset
against taxable income and income taxes in future years. The use of these losses
to reduce future income taxes will depend on the generation of sufficient
taxable income prior to the expiration of the net operating loss
carryforwards. The carryforwards expire in the year 2029. In the
event of certain changes in control, there will be an annual limitation on the
amount of net operating loss carryforwards which can be used. No tax benefit has
been reported in the financial statements for the period
ended June 30, 2009 because there is a 50% or greater chance that the
carryforward will not be used. Accordingly, the potential tax benefit of the
loss carryforward is offset by a valuation allowance of the same
amount.
Forward-Looking
and Cautionary Statements
This report, including the sections
entitled "Business," "Risk Factors" and "Management's Discussion and Analysis or
Plan of Operations" contains forward-looking statements. These statements relate
to future events or our future financial performance and involve known and
unknown risks and uncertainties. These factors may cause our Company's or our
industry's actual results, levels of activity, performance or achievements to be
materially different from those expressed or implied by the forward-looking
statements. These risks and other factors include those listed under "Risk
Factors" and elsewhere in this report. In some cases, you can identify
forward-looking statements by terminology such as "may," "will" "should,"
"expects," "intends," "plans,"
anticipates," "believes," "estimates," "predicts,"
"potential," "continue," or the negative of these terms or other comparable
terminology.
You should be aware that a variety of
factors could cause actual results to differ materially from the anticipated
results or other matters expressed in forward-looking
statements. These risks and uncertainties, many of which are beyond
our control, include:
12
* the
sufficiency of existing capital resources and our ability to raise additional
capital to fund cash requirements for future operations;
* uncertainties
following any successful acquisition or merger related to the future rate of
growth of our business and acceptance of our products and/or
services;
* volatility
of the stock market, particularly within the technology sector; and
* general
economic conditions.
Although we believe the expectations
reflected in these forward-looking statements are reasonable, such expectations
cannot guarantee future results, levels of activity, performance or
achievements.
You are cautioned that any
forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties. Actual results may differ
materially from those included within the forward-looking statements as a result
of various factors. Cautionary statements in the risk factors section
and elsewhere in this report identify important risks and uncertainties
affecting our future, which could cause actual results to differ materially from
the forward-looking statements made in this report.
Item
3. Quantitative and Qualitative Disclosures About Market
Risk.
A
“smaller reporting company” (as defined by Item 10 of Regulation S-K) is not
required to provide the information required by this Item.
Item
4. Controls and Procedures.
Under the
supervision and with the participation of management, our principal executive
officer and principal financial officer evaluated the effectiveness of the
design and operation of our disclosure controls and procedures, as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934
(“Exchange Act”), as of June 30, 2009. Based on this evaluation, our
principal executive officer and our principal financial officer concluded that,
as of the end of the period covered by this report, our disclosure controls and
procedures were not effective and adequately designed to ensure that the
information required to be disclosed by us in the reports we submit under the
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the applicable rules and forms and that such information
was accumulated and communicated to our chief executive officer and chief
financial officer, in a manner that allowed for timely decisions regarding
required disclosure.
During
the last fiscal quarter ended June 30, 2009, there has been no change in
internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect our internal control over financial
reporting.
ANY
FORWARD-LOOKING STATEMENTS INCLUDED IN THIS FORM 10-Q REPORT REFLECT
MANAGEMENT’S BEST JUDGMENT BASED ON FACTORS CURRENTLY KNOWN AND INVOLVE RISKS
AND UNCERTAINTIES. ACTUAL RESULTS MAY VARY MATERIALLY.
PART II -
OTHER INFORMATION
Item
1. Legal Proceedings.
There are
no material pending legal proceedings to which we or our subsidiary is a party
or to which any of our property is subject and, to the best of our knowledge, no
such action against us is contemplated or threatened.
13
Item
1A. Risk Factors.
A
“smaller reporting company” (as defined by Item 10 of Regulation S-K) is not
required to provide the information required by this Item.
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds.
During
the six month period ended June 30, 2009, the Company did not sell any shares of
its common stock without registration under the Securities Act of 1933, except
for the following:
|
Ø
|
The
Company received a total of $123,000 in gross offering proceeds from
subscriptions receivable from one
person during the six months ended June 30, 2009. The shares
were sold at $1.00 per share, and the shares had not been issued as of
June 30, 2009. The Company has
issued
123,000 shares of its common stock at $1.00 per share to the subscriber
during third quarter 2009. The shares were issued without
registration pursuant to Section 4(2) of the Securities Act of 1933 and/or
Rule 506 of Regulation D for transactions not involving any public
offering. Each purchaser represented that he is acquiring the
shares with investment intent, and the certificates representing the
shares will be given a restricted legend. Each purchaser
received a private placement memorandum prior to making his/her
investment.
|
For information concerning other
issuance of the Company’s common stock without registration under the Securities
Act of 1933 since January 1, 2006, see the Company’s annual reports on Forms
10-K or 10-KSB and the Company’s quarterly reports on Form 10-Q and 10-QSB filed
since January 1, 2006.
Item
3. Defaults Upon Senior Securities.
None;
not applicable.
Item
4. Submission of Matters to a Vote of Security
Holders.
None;
not applicable.
Item
5. Other Information.
None; not
applicable.
Item
6. Exhibits
(a)
Exhibits.
Exhibit
|
||
Number
|
Description
|
|
31.1
|
Certification
of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
31.2
|
Certification
of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002
|
|
32.1
|
Certification
of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002
|
|
32.2
|
Certification
of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002
|
14
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CURATECH
INDUSTRIES, INC.
|
||
Date:
December
10, 2009
|
By:
|
/s/ Lincoln M.
Dastrup
|
Lincoln
M. Dastrup
|
||
President,
Chief Executive Officer, Chief Financial Officer and Chief
Accounting
Officer
|
15